O
VRTX icon

Ossiam’s Vertex Pharmaceuticals VRTX Stock Holding History

Ossiam’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.6M Buy
39,357
+21,763
+124% +$10.1M 0.31% 53
2025
Q4 		$7.98M Buy
17,594
+4,654
+36% +$2.01M 0.16% 74
2025
Q3 		$5.07M Buy
12,940
+8,340
+181% +$3.49M 0.07% 203
2025
Q2 		$2.05M Sell
4,600
-66,608
-94% -$30.7M 0.02% 267
2025
Q1 		$34.5M Buy
71,208
+6,375
+10% +$2.97M 0.48% 43
2024
Q4 		$26.1M Buy
64,833
+435
+0.7% +$202K 0.45% 43
2024
Q3 		$30M Sell
64,398
-1,107
-2% -$532K 0.58% 40
2024
Q2 		$30.7M Buy
65,505
+54,411
+490% +$23.6M 0.58% 43
2024
Q1 		$4.64M Buy
11,094
+2,100
+23% +$888K 0.08% 148
2023
Q4 		$3.66M Buy
8,994
+1,238
+16% +$457K 0.06% 145
2023
Q3 		$2.7M Buy
7,756
+227
+3% +$79.4K 0.05% 170
2023
Q2 		$2.65M Sell
7,529
-91,574
-92% -$30.9M 0.05% 182
2023
Q1 		$31.2M Buy
99,103
+3,044
+3% +$913K 0.65% 41
2022
Q4 		$27.7M Buy
96,059
+1,765
+2% +$538K 0.72% 41
2022
Q3 		$27.3M Sell
94,294
-1,764
-2% -$508K 0.79% 29
2022
Q2 		$27.1M Buy
96,058
+1,984
+2% +$531K 0.81% 35
2022
Q1 		$24.6M Buy
94,074
+4,020
+4% +$954K 0.64% 37
2021
Q4 		$19.8M Buy
90,054
+87,369
+3,254% +$17M 0.52% 51
2021
Q3 		$487K Buy
2,685
+393
+17% +$76.7K 0.01% 315
2021
Q2 		$462K Sell
2,292
-2,676
-54% -$560K 0.01% 326
2021
Q1 		$1.07M Buy
4,968
+4,711
+1,833% +$1.03M 0.03% 212
2020
Q4 		$61K Buy
257
+205
+394% +$47K ﹤0.01% 378
2020
Q3 		$14K Sell
52
-2
-4% -$552 ﹤0.01% 379
2020
Q2 		$16K Sell
54
-3,357
-98% -$910K ﹤0.01% 412
2020
Q1 		$812K Buy
3,411
+2,858
+517% +$656K 0.06% 185
2019
Q4 		$121K Sell
553
-347
-39% -$70.2K 0.01% 367
2019
Q3 		$152K Buy
900
+590
+190% +$104K 0.01% 346
2019
Q2 		$57K Sell
310
-17,472
-98% -$3.05M ﹤0.01% 409
2019
Q1 		$3.27M Sell
17,782
-9,563
-35% -$1.77M 0.27% 77
2018
Q4 		$4.53M Buy
+27,345
New +$4.74M 0.68% 44

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ossiam's VRTX Position: Q1 2026 in Review

Ossiam increased its Vertex Pharmaceuticals (VRTX) stake by 124% in Q1 2026, buying an estimated $10.1M and bringing the position to 39,357 shares worth $17.6M. The position accounts for 0.31% of the portfolio, ranked #53.

Ossiam first reported a position in VRTX in Q4 2018 and has held it in 30 quarters since. The position peaked at $34.5M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ossiam held 39,357 shares of Vertex Pharmaceuticals worth $17.6M as of Q1 2026.
  • Ossiam bought 21,763 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.1M.
  • Vertex Pharmaceuticals made up 0.31% of Ossiam's portfolio in Q1 2026, its #53 holding.
  • Ossiam first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • Ossiam's Vertex Pharmaceuticals position peaked at $34.5M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ossiam's 13F filing for Q1 2026, filed 14 May 2026.